Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives

Journal of Hematology & Oncology, Journal Year: 2024, Volume and Issue: 17(1)

Published: April 29, 2024

Abstract Hepatocellular carcinoma (HCC) is a major health concern worldwide, with limited therapeutic options and poor prognosis. In recent years, immunotherapies such as immune checkpoint inhibitors (ICIs) have made great progress in the systemic treatment of HCC. The combination treatments based on ICIs been trend this area. Recently, dual blockade durvalumab plus tremelimumab has also emerged an effective for advanced However, majority HCC patients obtain benefits. Understanding immunological rationale exploring novel ways to improve efficacy immunotherapy drawn much attention. review, we summarize latest area, ongoing clinical trials immune-based therapies, well strategies chimeric antigen receptor T cells, personalized neoantigen vaccines, oncolytic viruses, bispecific antibodies.

Language: Английский

---

EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma

Journal of Hepatology, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 1, 2024

Language: Английский

---

Immunotherapy for hepatocellular carcinoma: The next evolution in expanding access to liver transplantation

Journal of Hepatology, Journal Year: 2024, Volume and Issue: 81(4), P. 743 - 755

Published: June 5, 2024

Language: Английский

---

Immunotherapy for hepatocellular carcinoma

JHEP Reports, Journal Year: 2024, Volume and Issue: 6(10), P. 101130 - 101130

Published: June 13, 2024

Language: Английский

---

Hepatocellular carcinoma: Revising the surgical approach in light of the concept of multiparametric therapeutic hierarchy

Digestive and Liver Disease, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

---

Liver diseases: epidemiology, causes, trends and predictions

Signal Transduction and Targeted Therapy, Journal Year: 2025, Volume and Issue: 10(1)

Published: Feb. 4, 2025

Abstract As a highly complex organ with digestive, endocrine, and immune-regulatory functions, the liver is pivotal in maintaining physiological homeostasis through its roles metabolism, detoxification, immune response. Various factors including viruses, alcohol, metabolites, toxins, other pathogenic agents can compromise function, leading to acute or chronic injury that may progress end-stage diseases. While sharing common features, diseases exhibit distinct pathophysiological, clinical, therapeutic profiles. Currently, contribute approximately 2 million deaths globally each year, imposing significant economic social burdens worldwide. However, there no cure for many kinds of diseases, partly due lack thorough understanding development these Therefore, this review provides comprehensive examination epidemiology characteristics covering spectrum from conditions manifestations. We also highlight multifaceted mechanisms underlying initiation progression spanning molecular cellular levels networks. Additionally, offers updates on innovative diagnostic techniques, current treatments, potential targets presently under clinical evaluation. Recent advances pathogenesis hold critical implications translational value novel strategies.

Language: Английский

---

Immunotherapy at all stages of hepatocellular carcinoma

Nature Medicine, Journal Year: 2024, Volume and Issue: 30(3), P. 640 - 641

Published: Feb. 26, 2024

Language: Английский

---

Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis

The Lancet Oncology, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 1, 2024

Language: Английский

---

Perioperative Tislelizumab plus intensity modulated radiotherapy in resectable hepatocellular carcinoma with macrovascular invasion: a phase II trial

Nature Communications, Journal Year: 2024, Volume and Issue: 15(1)

Published: Oct. 29, 2024

Language: Английский

---

The tumor distance to the main hepatic vessels is a predictor of recurrence-free survival and overall survival in hepatocellular cancer

Langenbeck s Archives of Surgery, Journal Year: 2025, Volume and Issue: 410(1)

Published: Jan. 9, 2025

Abstract Introduction The impact of the distance tumor from main hepatic vessels (DTV), such as Glissonean pedicle or veins, on oncological outcomes for Hepatocellular carcinoma (HCC) patients is relatively understudied. Therefore, objective this study was to explore correlation between DTV and survival in with HCC after curative resection. Methods Consecutive who underwent curative-intent liver surgery April 2018 May 2023 were identified a prospective database. Univariate multivariate Cox regression analysis performed identify independent predictors recurrence-free (RFS). A ROC-curve used find optimal cut-off value DTV. According estimated value, divided into 2 subgroups, then using Kaplan-Meier curve, RFS overall (OS) compared subgroups. Results In univariate analysis, DTV, size, resection margins, microvascular invasion (MVI) grading associated RFS. MVI confirmed ROC-analysis cutoff 20 mm. Patients < mm had larger size more advanced histopathological grading. There no difference presence both groups, while significantly experienced recurrence hepatectomy group. Accordingly, shorter median OS. Conclusion promising predictor OS HCC.

Language: Английский

---